PPIG and metabolic dysfunction-associated steatotic liver disease: NAFLD-associated changes in xenobiotic metabolizing enzyme activity might not be associated with higher toxic compound (i.e., the parent drugs or the CYP-generated reactive metabolites, or both) levels [15].